Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

AMIX

Autonomix Medical Inc.

Apr 29 • 04:00PM ET

3.32

Dollar change -0.04
Percentage change -1.19	%

Healthcare • Medical Devices • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: IWC VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-	Insider Own	56.40%	Shs Outstand	18.79M	Perf Week	9.89%
Market Cap	62.38M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	8.19M	Perf Month	9.93%
Income	-	PEG	-	EPS next Q	-	Inst Own	0.00%	Short Float	0.58%	Perf Quarter	-34.52%
Sales	-	P/S	-	EPS this Y	-	Inst Trans	-	Short Ratio	0.67	Perf Half Y	-
Book/sh	-0.30	P/B	-	EPS next Y	-	ROA	-	Short Interest	0.05M	Perf Year	-
Cash/sh	0.06	P/C	51.13	EPS next 5Y	-	ROE	-	52W Range	2.50 - 7.60	Perf YTD	-34.52%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-56.32%	Beta	-
Dividend TTM	-	Quick Ratio	1.73	Sales past 5Y	0.00%	Gross Margin	-	52W Low	32.80%	ATR (14)	0.30
Dividend Ex-Date	-	Current Ratio	1.73	EPS Y/Y TTM	-	Oper. Margin	-	RSI (14)	58.29	Volatility	6.95% 8.38%
Employees	-	Debt/Eq	-	Sales Y/Y TTM	-	Profit Margin	-	Recom	-	Target Price	-
Option/Short	No / Yes	LT Debt/Eq	-	EPS Q/Q	-	Payout	-	Rel Volume	0.26	Prev Close	3.36
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-	Earnings	-	Avg Volume	71.23K	Price	3.32
SMA20	13.93%	SMA50	2.29%	SMA200	-8.37%	Trades		Volume	18,180	Change	-1.19%

Apr-25-24 08:30AM	Autonomix Enters into Agreement with NoiseFigure Research, Inc. to Develop Next Generation of its Proprietary Microchip (GlobeNewswire) +6.84%
Apr-24-24 09:00AM	Autonomix to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar (GlobeNewswire)
Apr-16-24 09:00AM	Autonomix Announces Issuance of U.S. Patent Covering Proprietary Catheter-Based Technology for the Treatment of Cancer Related Pain (GlobeNewswire) -5.42%
Apr-15-24 12:03PM	Autonomix Medical Inc. Covered in Benzinga Article Highlighting Innovative Nerve Treatment Technology (News Direct)
Apr-11-24 08:55AM	Autonomix Medical (NASDAQ: AMIX) Is Cracking the Code Of The Peripheral Nervous System With Its Breakthrough Technology To Treat Diseases (News Direct)
08:30AM	Loading…
Apr-09-24 08:30AM	Autonomix Announces Positive Findings from Preclinical Study Demonstrating Potential to Improve Renal Denervation (GlobeNewswire)
Apr-08-24 08:30AM	Autonomix to Participate in the Virtual Investor Lunch Break: The Team Behind the AMIX Ticker (GlobeNewswire)
Mar-27-24 09:00AM	Autonomix to Present at the MedInvest Biotech & Pharma Investor Conference (GlobeNewswire)
Mar-20-24 08:05AM	Autonomix (NASDAQ: AMIX) to Present at the Benzinga Virtual Healthcare Summit 2024 (GlobeNewswire)
Mar-19-24 08:45AM	Autonomix Appoints Jennifer Cook as Chief Business Officer (GlobeNewswire)
Mar-14-24 08:15AM	Autonomix Completes First Three Patient Procedures in Human Clinical Trial Targeting Multi-Billion-Dollar Pancreatic Cancer Market (GlobeNewswire) +16.33%
Mar-06-24 08:00AM	Autonomix Enrolls First Patients in Human Clinical Trial Targeting Multi-Billion-Dollar Pancreatic Cancer Market (GlobeNewswire) -7.08%
Feb-29-24 08:30AM	Autonomix Signs Key Clinical Agreements in Preparation to Begin March 2024 Human Clinical Trial (GlobeNewswire) -7.83%
Feb-23-24 08:50AM	Autonomix Medical, Inc. (NASDAQ: AMIX) to Participate in the Virtual Investor Lunch Break: The Autonomix Opportunity (GlobeNewswire) +10.20%
Feb-22-24 08:00AM	Autonomix Secures Principal Investigators and Completes Clinical Training for First Human Study (GlobeNewswire)
08:00AM	Loading…
Feb-16-24 08:00AM	Autonomix Begins Human POC Clinical Trial Targeting Multi-Billion-Dollar Pancreatic Cancer Market (GlobeNewswire)
Feb-14-24 08:05AM	Autonomix Medical, Inc. Reports Third Quarter FY2024 Financial Results and Reiterates Upcoming Key Milestones (GlobeNewswire) -10.15%
Feb-09-24 08:45AM	Autonomix Medical, Inc. (NASDAQ:AMIX) to Present at Integrous Big Hearts, Big Ideas Virtual Investor Conference (ACCESSWIRE)
Feb-06-24 08:50AM	Autonomix Medical, Inc. Receives Ethics Committee Authorization for Proof-of-Concept Human Clinical Study Evaluating Proprietary Ablation Technology for Treatment of Pancreatic Cancer Pain (GlobeNewswire)
Feb-01-24 08:35AM	Autonomix Medical, Inc. (NASDAQ: AMIX) to Present at the Virtual Investor New to the Street Event (GlobeNewswire) +10.79%
Jan-31-24 08:45AM	Autonomix Medical, Inc. to Ring the Nasdaq Stock Market Closing Bell on Thursday, February 1, 2024 (GlobeNewswire)
Jan-30-24 12:00PM	Autonomix Medical, Inc. Completes $8,000,000 Transaction for Exclusive Worldwide Rights to Technology for Cardiology Field Use Over 100 patents in portfolio (GlobeNewswire)
09:05AM	Autonomix Medical, Inc. Completes Transaction for Exclusive Worldwide Rights to Technology for Cardiology Field Use (GlobeNewswire)
Jan-29-24 08:05AM	Autonomix Medical, Inc. (NASDAQ: AMIX) Commences Trading on NASDAQ (GlobeNewswire)

Autonomix Medical, Inc. is a development stage medical device development company focused on advancing innovative technologies for sensing and treating disorders relating to the nervous system. Its technology platform includes a catheter-based microchip-enabled array that can detect and differentiate neural signals with a high degree of sensitivity as demonstrated in animal studies. The company was founded by Robert Schwartz, Landy Toth, David A. Robins, and Robert A. Van Tassel on July 10, 2014 and is headquartered in Doylestown, PA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AMIX

Autonomix Medical Inc.

Upgrade your FINVIZ experience